Fact-check: Yale Medicine on how obesity medicine works

What the video covers

A Yale obesity medicine physician makes one argument in four minutes. Obesity is a neurometabolic disease. Lifestyle change produces some loss but the body fights to restore it, because the brain defends a fat-mass set point that the modern environment has pushed upward. Nutrient-stimulated hormones released by eating tell the brain how much energy is stored; the new medications imitate those hormones and act on brain receptors to re-regulate the set point, and weight loss follows. Lifestyle remains essential for health and prevention, but once the disease exists it needs treatment aimed at its mechanism, and stigma has no place in that.

What it gets right

The framework is mainstream. The observation that weight lost by diet is usually regained, and that hunger and reduced energy expenditure persist after loss, is well documented; the language of a defended set point is how many obesity researchers describe it. The description of GLP-1 and related drugs as nutrient-stimulated hormone mimetics acting centrally is accurate for semaglutide and tirzepatide, whose labels describe central appetite effects alongside gut and pancreatic ones. The evolutionary explanation is offered as a plausible story rather than a proven one, which is the right tone.

The clinical claim, that medications and surgery hold weight loss better than lifestyle alone, is supported. Look AHEAD's intensive lifestyle arm was at 8.6 percent loss at one year and 6.2 percent at four years (PubMed 20876408). STEP 1 produced 14.9 percent at 68 weeks with semaglutide (PubMed 33567185), and STEP 4 showed that stopping the drug reversed the loss (PubMed 33755728), which is the set-point model's prediction.

What it leaves out or overstates

The video gives no efficacy numbers for anything, so a viewer cannot weigh lifestyle against medication against surgery except by the speaker's characterisation. The set-point model is also simpler than the field. Whether there is a single defended level, whether it is reset or merely overridden while the drug is present, and how much of the effect is on reward and food noise rather than homeostatic hunger, are open questions; the STEP 4 regain is equally consistent with "the drug suppresses appetite while it is on board" as with "the drug reset the set point".

The video also says nothing about side effects, cost, or who the drugs are indicated for, and nothing about how much lifestyle still matters during pharmacotherapy for lean mass and cardiorespiratory fitness. Its companion videos in this playlist fill some of that in.

Where to go next

Watch the two other Yale Medicine videos next: one on where medication fits, one on what lifestyle can and cannot do. FormBlends Science has diagrams of the appetite circuits and a page on why weight returns. For the withdrawal-trial arithmetic applied to your own weight, use the maintenance planner on Weight Loss on GLP-1s. The FormBlends tirzepatide guide is at formblends.com; compounded GLP-1s from FormBlends are not FDA approved.